Abstract Search

ea0016s30.5 | Clinical highlights | ECE2008

Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline: dose and treatment duration effect

Colao Annamaria , Galderisi Maurizio , Sarno Antonella Di , Pardo Moira , Gaccione Maria , D'Andrea Marianna , Pivonello Rosario , Guerra Ermelinda , Lerro Giuseppe , Lombardi Gaetano

Background: Cabergoline, a dopamine receptor-2 agonist, used to treat prolactinomas was associated with increased risk of cardiac valve disease.Objective: To evaluate prevalence of cardiac valve regurgitation in patients with prolactinomas treated with cabergoline.Design: Open, casecontrol, prospective.Patients: Fifty patients (44 women, 6 men) and 50 sex- and age-matched control subjects.<p class="...

0 shares

Endocrine Abstracts

Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline: dose and treatment duration effect

BiosciAbstracts